



Synta to Present at the Jefferies 2015 Global Healthcare Conference

May 27, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)--May 27, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, at 11:30 a.m. (ET) in New York.

A live [webcast](#) and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150527006523/en/>

Source: Synta Pharmaceuticals Corp.

Investors:

Synta Pharmaceuticals Corp.

Daniel Cole, 781-541-7250

dcole@syntapharma.com

or

Argot Partners

Andrea Rabney, 212-600-1494

andrea@argotpartners.com

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

eliza@argotpartners.com